- Home
- RARE vs SAH Comparison
RARE vs SAH Comparison
Compare RARE & SAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- SAH
- Stock Information
- Founded
- RARE 2010
- SAH 1997
- Country
- RARE United States
- SAH United States
- Employees
- RARE N/A
- SAH N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- SAH Other Specialty Stores
- Sector
- RARE Health Care
- SAH Consumer Discretionary
- Exchange
- RARE Nasdaq
- SAH Nasdaq
- Market Cap
- RARE 3.1B
- SAH 2.8B
- IPO Year
- RARE 2014
- SAH 1997
- Fundamental
- Price
- RARE $33.28
- SAH $77.55
- Analyst Decision
- RARE Strong Buy
- SAH Buy
- Analyst Count
- RARE 13
- SAH 8
- Target Price
- RARE $87.69
- SAH $82.50
- AVG Volume (30 Days)
- RARE 1.5M
- SAH 153.0K
- Earning Date
- RARE 11-03-2025
- SAH 10-23-2025
- Dividend Yield
- RARE N/A
- SAH 1.96%
- EPS Growth
- RARE N/A
- SAH N/A
- EPS
- RARE N/A
- SAH 4.52
- Revenue
- RARE $610,159,000.00
- SAH $14,695,800,000.00
- Revenue This Year
- RARE $19.72
- SAH $4.81
- Revenue Next Year
- RARE $23.29
- SAH $3.59
- P/E Ratio
- RARE N/A
- SAH $17.11
- Revenue Growth
- RARE 26.77
- SAH 4.48
- 52 Week Low
- RARE $25.81
- SAH $52.00
- 52 Week High
- RARE $56.38
- SAH $89.62
- Technical
- Relative Strength Index (RSI)
- RARE 58.42
- SAH 55.43
- Support Level
- RARE $32.40
- SAH $70.70
- Resistance Level
- RARE $34.78
- SAH $76.68
- Average True Range (ATR)
- RARE 1.26
- SAH 2.18
- MACD
- RARE 0.27
- SAH 0.57
- Stochastic Oscillator
- RARE 71.21
- SAH 95.74
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About SAH Sonic Automotive Inc.
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 108 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores, 16 collision centers, and 14 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 59% of new-vehicle revenue. BMW is the largest brand at about 25%. 2024's revenue was $14.2 billion, with Texas and California comprising 51% of the total. EchoPark's portion was $2.1 billion.